




**Figure 1. Anti-Cln101 MAbs Epitope Map**




**Figure 2. Detection of Cln101 in Normal and Cancer Serum Samples (primary panel)**




**Figure 3. Detection of Cln101 in Normal and Cancer Serum Samples (primary panel), Expanded Scale**




**Figure 4. Detection of Cln101 in Normal and Cancer Serum Samples (multiple panels)**




**Figure 5. Detection of Cln101 in Normal and Cancer Serum Samples (multiple panels), Expanded Scale**



**Figure 6. Detection of Cln101 in Normal and Cancer Serum Samples (master panel)**



**Figure 7. Detection of Cln101 in Normal and Cancer Serum Samples (master panel), Expanded Scale**



**Figure 8. Detection of Cln101 in Normal, Prostate Cancer and Prostate Benign Serum Samples**






Figure 9. Detection of PSA in Normal, Prostate Cancer and Prostate Benign Serum Samples







Figure 10. Detection of Cln101 in Normal, Ovarian Cancer and Ovarian Benign Serum Samples



**Figure 11. ROC Curves for CLN101 and PSA in Prostate Cancer vs. Normal Serum Samples**



**Figure 12. ROC Curves for CLN101 and PSA in Prostate Cancer and Benign Disease vs. Normal Serum Samples**



**AUC = 0.741**

**AUC = 0.762**